Rate and predictors of treatment prescription for hepatitis C

被引:123
作者
Butt, Adeel A.
Justice, Amy C.
Skanderson, Melissa
Rigsby, Michael O.
Good, Chester B.
Kwoh, C. Kent
机构
[1] Univ Pittsburgh, Med Ctr, Sch Med, VA Pittsburgh Healthcare Syst,Ctr Hlth Equ Res &, Pittsburgh, PA 15213 USA
[2] Yale Univ, Sch Med, New Haven, CT 06520 USA
[3] VA Connecticut Healthcare Syst, West Haven, CT USA
关键词
D O I
10.1136/gut.2006.099150
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The true treatment rate for hepatitis C virus (HCV) in veterans is unknown. Aim: To determine the treatment prescription rates and predictors of treatment prescription for HCV in a large national population. Methods: The Department of Veterans Affairs National Patient Care Database (NPCD) was used to identify all HCV-infected people between the fiscal years 1999 and 2003 using the International classification of diseases, 9th revision codes. Demographic information, medical and psychiatric comorbidities, and drug and alcohol use diagnoses were retrieved. Pharmacy data were retrieved from the Department of Veterans Affairs Pharmacy Benefits Management (PBM) database. Logistic regression analysis was used to determine the predictors of treatment for HCV in HCV. Results: 113 927 veterans in the Department of Veterans Affairs care with a diagnosis of HCV were identified. The treatment prescription rate for HCV was 11.8%. Patients not prescribed treatment were older, more likely to be from minority races, have more alcohol and drug misuse, and have medical and psychiatric comorbid conditions. In a multivariate logistic regression model, the following factors were predictive of non-treatment for HCV: increasing age ( odds ratio ( OR) 0.77 for each 5-year increase in age; 95% confidence interval (CI) 0.76 to 0.78); black race ( OR 0.64; 95% CI 0.6 to 0.68); Hispanic race ( OR 0.88; 95% CI 0.8 to 0.96); alcohol abuse and dependence ( OR 0.62; 95% CI 0.59 to 0.65); drug abuse and dependence ( OR 0.78; 95% CI 0.74 to 0.82); anaemia ( OR 0.18; 95% CI 0.16 to 0.21); hepatitis B infection ( OR 0.72; 95% CI 0.62 to 0.83); coronary artery disease ( OR 0.9; 95% CI 0.85 to 0.97); stroke ( OR 0.75; 95% CI 0.67 to 0.85); bipolar disorder ( OR 0.64; 95% CI 0.58 to 0.70); major depression ( OR 0.72; 95% CI 0.67 to 0.77); mild depression ( OR 0.56; 95% CI 0.53 to 0.59); and schizophrenia ( OR 0.71; 95% CI 0.65 to 0.77). The following factors were associated with a higher likelihood of treatment prescription for HCV: liver cirrhosis ( OR 1.6; 95% CI 1.5 to 1.7); and diabetes ( OR 1.07; 95% CI 1.02 to 1.12). Conclusions: A small number of HCV-infected veterans were prescribed treatment for HCV. Non-treatment is associated with increasing age, non-white race, drug and alcohol abuse, and dependence and comorbid illnesses. Reasons for non-treatment need further study.
引用
收藏
页码:385 / 389
页数:5
相关论文
共 31 条
[1]   The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[2]  
[Anonymous], 2002, NIH Consens State Sci Statements, V19, P1
[3]   Racial differences in the treatment of early-stage lung cancer [J].
Bach, PB ;
Cramer, LD ;
Warren, JL ;
Begg, CB .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (16) :1198-1205
[4]  
Booth JC, 2001, GUT S1, V49, P11
[5]   Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection [J].
Bozzette, SA ;
Ake, CF ;
Tam, HK ;
Chang, SW ;
Louis, TA .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (08) :702-710
[6]   Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects [J].
Butt, A. A. ;
Justice, A. C. ;
Skanderson, M. ;
Good, C. ;
Kwoh, C. K. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (04) :585-591
[7]   Risk of diabetes in HIV infected veterans pre- and Post-HAART and the role of HCV coinfection [J].
Butt, AA ;
Fultz, SL ;
Kwoh, CK ;
Kelley, D ;
Skanderson, M ;
Justice, AC .
HEPATOLOGY, 2004, 40 (01) :115-119
[8]   Reasons for non-treatment of hepatitis C in veterans in care [J].
Butt, AA ;
Wagener, M ;
Shakil, AO ;
Ahmad, J .
JOURNAL OF VIRAL HEPATITIS, 2005, 12 (01) :81-85
[9]   Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons [J].
Chung, RT ;
Andersen, J ;
Volberding, P ;
Robbins, GK ;
Liu, T ;
Sherman, KE ;
Peters, MG ;
Koziel, MJ ;
Bhan, AK ;
Alston, B ;
Colquhoun, D ;
Nevin, T ;
Harb, G ;
van der Horst, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :451-459
[10]   Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C [J].
Davis, GL ;
Esteban-Mur, R ;
Rustgi, V ;
Hoefs, J ;
Gordon, SC ;
Trepo, C ;
Shiffman, ML ;
Zeuzem, S ;
Craxi, A ;
Ling, MH ;
Albrecht, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1493-1499